236 related articles for article (PubMed ID: 27659531)
1. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
[TBL] [Abstract][Full Text] [Related]
2. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
[TBL] [Abstract][Full Text] [Related]
5. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M
Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794
[TBL] [Abstract][Full Text] [Related]
6. TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
Spranger S; Jeremias I; Wilde S; Leisegang M; Stärck L; Mosetter B; Uckert W; Heemskerk MH; Schendel DJ; Frankenberger B
Blood; 2012 Apr; 119(15):3440-9. PubMed ID: 22371883
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Meier C; Schmitt A; Spitschak A; Hilgendorf I; Rohde S; Hirt C; Freund M; Pützer BM; Schmitt M
Clin Dev Immunol; 2012; 2012():146463. PubMed ID: 22719778
[TBL] [Abstract][Full Text] [Related]
8. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
9. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
Schmitt M; Schmitt A; Rojewski MT; Chen J; Giannopoulos K; Fei F; Yu Y; Götz M; Heyduk M; Ritter G; Speiser DE; Gnjatic S; Guillaume P; Ringhoffer M; Schlenk RF; Liebisch P; Bunjes D; Shiku H; Dohner H; Greiner J
Blood; 2008 Feb; 111(3):1357-65. PubMed ID: 17978170
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of dendritic cells transfected with mRNA for receptor for hyaluronan-mediated motility is mediated by CD4+ T cells.
Fukui M; Ueno K; Suehiro Y; Hamanaka Y; Imai K; Hinoda Y
Cancer Immunol Immunother; 2006 May; 55(5):538-46. PubMed ID: 16025267
[TBL] [Abstract][Full Text] [Related]
11. Acute lymphoblastic leukemia-derived dendritic cells express tumor associated antigens: PNPT1, PMPCB, RHAMM, BSG and ERCC1.
Luczynski W; Kowalczuk O; Stasiak-Barmuta A; Ilendo E; Krawczuk-Rybak M; Chyczewski L
Neoplasma; 2009; 56(5):428-34. PubMed ID: 19580345
[TBL] [Abstract][Full Text] [Related]
12. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
13. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
[TBL] [Abstract][Full Text] [Related]
15. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
Greiner J; Döhner H; Schmitt M
Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
[TBL] [Abstract][Full Text] [Related]
17. Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.
Tabarkiewicz J; Giannopoulos K
Transplant Proc; 2010 Oct; 42(8):3293-6. PubMed ID: 20970674
[TBL] [Abstract][Full Text] [Related]
18. Targeting of the WT1
Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
[TBL] [Abstract][Full Text] [Related]
19. mRNA-based dendritic cell vaccines.
Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
[TBL] [Abstract][Full Text] [Related]
20. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]